Developer docs
API playgroundTry for free, no card

Search company profiles

Puma Biotechnology

Full company profile

uuid00038m8

Namestring
Puma Biotechnology
Legal namestring
Puma Biotechnology, Inc.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Puma Biotechnology, Inc. is a US-based, publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, California, focused on the development and commercialization of oncology therapies. The company's commercial portfolio centers on NERLYNX (neratinib), an oral small molecule tyrosine kinase inhibitor that received FDA approval in 2017 as extended adjuvant therapy for HER2-positive early-stage breast cancer. NERLYNX generated $204.1M of the company's $228.4M in FY2025 revenue, making it the sole marketed product and primary growth driver. Puma also advances a pipeline candidate, alisertib (an Aurora A kinase inhibitor), in Phase II clinical trials for breast cancer (ALISCA-Breast1, 164 patients enrolled) and small-cell lung cancer (ALISCA-Lung1, with Q2 2026 interim data expected at 60mg BID dosing). The company has achieved three consecutive years of profitability (2023-2025), reporting FY2025 net income of $31.1M.

Puma commercializes NERLYNX through a US specialty pharmaceutical field sales organization targeting oncologists and cancer treatment centers, with international expansion initiated via a Thailand launch in January 2026 following Thai FDA approval in December 2024. Revenue derives from two streams: NERLYNX product sales and royalty income from licensed intellectual property ($15.6M in Q4 2025). Management has guided 2026 NERLYNX product revenue to $194-198M and royalty revenue to $20-23M. The company is led by founder Alan H. Auerbach as Chairman, CEO and President, and operates as an independent entity with no parent company, having secured debt financing from Athyrium Capital Management ($125M note purchase agreement, 2021) and a small private placement ($10M, March 2022) as its primary capital events. In December 2025 Puma was added to the Nasdaq Biotechnology Index, reflecting its commercialization and profitability milestones.

The company's competitive positioning rests on regulatory exclusivity for NERLYNX in the HER2-positive extended adjuvant setting, an established specialty oncology distribution network, and proprietary pipeline assets. Principal strategic risks include single-product revenue concentration, the absence of meaningful diversification beyond HER2+ breast cancer, and the early-stage nature of the alisertib pipeline. Growth levers include international geographic expansion, indication broadening for neratinib and alisertib, and potential pipeline partnering or licensing transactions.

Short descriptiontext

Puma Biotechnology is a US biopharmaceutical company (NASDAQ: PBYI) that develops and commercializes oncology therapies, primarily NERLYNX (neratinib), an FDA-approved oral tyrosine kinase inhibitor for HER2-positive breast cancer, with a Phase II pipeline candidate (alisertib) in breast and lung cancers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
251–500
akta.pro rankint
HeadquartersLos Angeles, United States
HQ citystring
Los Angeles
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oncology therapeutics, HER2 breast cancer, tyrosine kinase inhibitors, cancer drug development, biopharmaceutical products
Industry2 codes
PRIMARYHLAKAFAB
Medical Oncology
SECONDARYHLAKAFAJ
Breast Oncology
NAICS code1 code
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1NERLYNX Product Revenue
TypeOne Time License
Description

Sales of FDA-approved drug NERLYNX (neratinib) for HER2-positive breast cancer. Revenue from $2.79 private placement in 2022 and $100M Athyrium financing in 2021 has supported commercialization.

businesswire.com
2Royalty Revenue
TypeLicensing Royalties
Description

Royalty income from licensed intellectual property and international partnerships. Q4 2025 royalties were $15.6 million. Full year 2025 royalty revenue was $20-23 million.

businesswire.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Marketing or Sales, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1NERLYNX
Description

FDA-approved drug for HER2-positive breast cancer treatment

finance.yahoo.com
+1 more record
Core offering1 text field

Puma Biotechnology develops and commercializes oncology therapeutics, with its primary product being NERLYNX (neratinib), an FDA-approved oral small-molecule tyrosine kinase inhibitor for the extended adjuvant treatment of HER2-positive early-stage breast cancer. The company also develops alisertib, an Aurora A kinase inhibitor currently in Phase II clinical trials for HER2-positive breast cancer and small-cell lung cancer.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing cancer care products. The company's commercial portfolio centers on NERLYNX (neratinib), an FDA-approved HER2-positive breast cancer therapy that represents the company's sole marketed product and primary revenue driver. The pipeline includes alisertib, an experimental drug in Phase II studies for breast cancer and small-cell lung cancer. The company has maintained profitability for three consecutive years, reporting full-year 2025 net income of $31.1 million on revenue of $228.4 million.

Product and service2 records
1NERLYNX (neratinib)
CategoryOncology Therapeutics
2Alisertib
CategoryOncology Pipeline Candidate
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Puma Biotechnology

Oncology Pharmaceuticalspumabiotechnology.com

Puma Biotechnology is a US biopharmaceutical company (NASDAQ: PBYI) that develops and commercializes oncology therapies, primarily NERLYNX (neratinib), an FDA-approved oral tyrosine kinase inhibitor for HER2-positive breast cancer, with a Phase II pipeline candidate (alisertib) in breast and lung cancers.

What Puma Biotechnology does

Puma Biotechnology, Inc. is a US-based, publicly traded biopharmaceutical company (NASDAQ: PBYI) headquartered in Los Angeles, California, focused on the development and commercialization of oncology therapies. The company's commercial portfolio centers on NERLYNX (neratinib), an oral small molecule tyrosine kinase inhibitor that received FDA approval in 2017 as extended adjuvant therapy for HER2-positive early-stage breast cancer. NERLYNX generated $204.1M of the company's $228.4M in FY2025 revenue, making it the sole marketed product and primary growth driver. Puma also advances a pipeline candidate, alisertib (an Aurora A kinase inhibitor), in Phase II clinical trials for breast cancer (ALISCA-Breast1, 164 patients enrolled) and small-cell lung cancer (ALISCA-Lung1, with Q2 2026 interim data expected at 60mg BID dosing). The company has achieved three consecutive years of profitability (2023-2025), reporting FY2025 net income of $31.1M.

Puma commercializes NERLYNX through a US specialty pharmaceutical field sales organization targeting oncologists and cancer treatment centers, with international expansion initiated via a Thailand launch in January 2026 following Thai FDA approval in December 2024. Revenue derives from two streams: NERLYNX product sales and royalty income from licensed intellectual property ($15.6M in Q4 2025). Management has guided 2026 NERLYNX product revenue to $194-198M and royalty revenue to $20-23M. The company is led by founder Alan H. Auerbach as Chairman, CEO and President, and operates as an independent entity with no parent company, having secured debt financing from Athyrium Capital Management ($125M note purchase agreement, 2021) and a small private placement ($10M, March 2022) as its primary capital events. In December 2025 Puma was added to the Nasdaq Biotechnology Index, reflecting its commercialization and profitability milestones.

The company's competitive positioning rests on regulatory exclusivity for NERLYNX in the HER2-positive extended adjuvant setting, an established specialty oncology distribution network, and proprietary pipeline assets. Principal strategic risks include single-product revenue concentration, the absence of meaningful diversification beyond HER2+ breast cancer, and the early-stage nature of the alisertib pipeline. Growth levers include international geographic expansion, indication broadening for neratinib and alisertib, and potential pipeline partnering or licensing transactions.

Puma Biotechnology firmographics

Firmographics
Name
Puma Biotechnology
Legal name
Puma Biotechnology, Inc.
Website
https://pumabiotechnology.com
Company type
Public
Founded year
2017
Operating status
Operating
Headcount range
251–500 employees
Short description
Puma Biotechnology is a US biopharmaceutical company (NASDAQ: PBYI) that develops and commercializes oncology therapies, primarily NERLYNX (neratinib), an FDA-approved oral tyrosine kinase inhibitor for HER2-positive breast cancer, with a Phase II pipeline candidate (alisertib) in breast and lung cancers.
Ownership category
akta.pro rank

Puma Biotechnology industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAFAB
Medical Oncology
SECONDARYHLAKAFAJ
Breast Oncology

Keywords

  • Oncology therapeutics
  • HER2 breast cancer
  • Tyrosine kinase inhibitors
  • Cancer drug development
  • Biopharmaceutical products

Where Puma Biotechnology is headquartered

Location

Headquarters

HQ city
Los Angeles
HQ country
United States
HQ region
North America

Markets served

Puma Biotechnology business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Marketing or Sales, Personnel, Operations, Others

Revenue model

  1. NERLYNX Product Revenue: Sales of FDA-approved drug NERLYNX (neratinib) for HER2-positive breast cancer. Revenue from $2.79 private placement in 2022 and $100M Athyrium financing in 2021 has supported commercialization.
  2. Royalty Revenue: Royalty income from licensed intellectual property and international partnerships. Q4 2025 royalties were $15.6 million. Full year 2025 royalty revenue was $20-23 million.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Puma Biotechnology product offering

Product offering

Core offering

Puma Biotechnology develops and commercializes oncology therapeutics, with its primary product being NERLYNX (neratinib), an FDA-approved oral small-molecule tyrosine kinase inhibitor for the extended adjuvant treatment of HER2-positive early-stage breast cancer. The company also develops alisertib, an Aurora A kinase inhibitor currently in Phase II clinical trials for HER2-positive breast cancer and small-cell lung cancer.

Product overview

Puma Biotechnology is a biopharmaceutical company focused on developing and commercializing cancer care products. The company's commercial portfolio centers on NERLYNX (neratinib), an FDA-approved HER2-positive breast cancer therapy that represents the company's sole marketed product and primary revenue driver. The pipeline includes alisertib, an experimental drug in Phase II studies for breast cancer and small-cell lung cancer. The company has maintained profitability for three consecutive years, reporting full-year 2025 net income of $31.1 million on revenue of $228.4 million.

Differentiator

Problem solved

Functional benefit

Brands

  • NERLYNX: FDA-approved drug for HER2-positive breast cancer treatment
  • Alisertib

Products and services

  • NERLYNX (neratinib)
  • Alisertib

Companies that use Puma Biotechnology

Customer profile

Segments2 records

Ideal customer profiles2 records

Puma Biotechnology technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Puma Biotechnology partnerships and signals

Strategic signal

Scale indicators10 records

Recent moves3 records

Expansion highlights5 records

Puma Biotechnology competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Puma Biotechnology financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Puma Biotechnology leadership team

Management profile

Number of profiles

Profiles4 records

Puma Biotechnology funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Puma Biotechnology M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Puma Biotechnology

What does Puma Biotechnology do?

Puma Biotechnology develops and commercializes oncology therapeutics, with its primary product being NERLYNX (neratinib), an FDA-approved oral small-molecule tyrosine kinase inhibitor for the extended adjuvant treatment of HER2-positive early-stage breast cancer. The company also develops alisertib, an Aurora A kinase inhibitor currently in Phase II clinical trials for HER2-positive breast cancer and small-cell lung cancer.

Is Puma Biotechnology a public or private company?

Puma Biotechnology is a public company. It is classified as public and is currently operating.

When was Puma Biotechnology founded?

Puma Biotechnology was founded in 2017. It employs 251 to 500 people.

Where is Puma Biotechnology based?

Puma Biotechnology is headquartered in Los Angeles, United States, in the North America region.

How does Puma Biotechnology make money?

Two revenue lines are on record. NERLYNX Product Revenue is the primary driver. The others are royalty Revenue.

Does Puma Biotechnology have an API?

No public API is recorded for Puma Biotechnology.

What industry is Puma Biotechnology in?

Puma Biotechnology's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAKAFAB, Medical Oncology, with a secondary code of HLAKAFAJ, Breast Oncology. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NasdaqPuma: 3 Key Takeaways for Long-Term InvestorsPuma Biotechnology reported Q3 2026 revenue of $55.1 million and became debt-free after paying off its Athyrium loan. Generic competition in China cut royalty revenue by $2.1 million, prompting a lower full-year royalty guidance. The company plans a phase III breast cancer trial for alisertib in 2027.The Motley FoolPuma: 3 Key Takeaways for Long-Term InvestorsPuma reported Q3 2026 revenue of $55.1 million and became debt-free after paying off its Athyrium loan. Generic competition in China cut royalty revenue by $2.1 million, prompting a lower full-year royalty guidance. The company plans a phase III trial for alisertib in 2027.MarketBeatPuma Biotechnology Q3 Earnings Call HighlightsPuma Biotechnology reported Q3 2026 revenue of $55.1 million and raised its full-year net income forecast to $20-22 million. It lowered royalty and NERLYNX sales guidance, citing China generic competition. The company plans to discuss a phase III trial of alisertib with regulators in H1 2027.The future of tradingPuma Biotechnology Q3 2026 net income falls 32% to $6 millionPuma Biotechnology reported Q3 2026 net income of $6 million, down 32% year over year, with revenue rising to $55.1 million and R&D expenses climbing 15% to $18.3 million. The company initiated ALISCA-Lung2, a Phase II trial for alisertib with paclitaxel in advanced small cell lung cancer, and raised its full-year 2026 net income guidance to $20–22 million.TradingViewPuma Biotechnology Q3 2026 Earnings Call Is LivePuma Biotechnology's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary on demand, margins, or capital spending could move markets.TradingViewPBYI: FY 2026 net income guidance rises as U.S. NERLYNX demand grows amid gross-to-net pressurePuma Biotechnology reported Q3 revenue of $55.1M, with GAAP and adjusted net income declining year-over-year. The company raised its FY2026 net income guidance to $20-22M, citing U.S. NERLYNX demand growth offset by gross-to-net pressure.Investing.comUp +10% premarket, this AI-picked biotech heads into Q3 after a 533% EPS surprisePuma Biotechnology shares rose 10.38% in premarket trading ahead of its Q3 earnings report, following a Q2 EPS beat of 533% on diluted EPS of $0.16 versus $0.03 expected. The company reported revenue of $56.5 million and raised full-year guidance, with NERLYNX demand rising for two consecutive years.MarketBeatPuma Biotechnology (PBYI) Expected to Post Earnings on ThursdayPuma Biotechnology is expected to report Q3 2026 earnings on Thursday, November 5th, with analysts projecting $0.09 EPS and $57.50 million revenue. The company's stock opened at $10.62, and insiders sold shares under a pre-arranged plan. Analysts have an average rating of Moderate Buy with a price target of $6.00.Ticker ReportAnalyzing Puma Biotechnology (NASDAQ:PBYI) & BridgeBio Pharma (NASDAQ:BBIO)BridgeBio Pharma and Puma Biotechnology are compared on dividends, earnings, risk, profitability, analyst recommendations, institutional ownership, and valuation. BridgeBio has a stronger consensus rating, higher upside, and lower beta, while Puma shows higher profitability and institutional ownership. BridgeBio's consensus price target is $104.40, implying 52.36% upside.Zacks4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthAstraZeneca, Roche, Puma Biotechnology, and Olema Oncology are highlighted for breast cancer investment opportunities. Roche's Phesgo sales rose 18% to $1.68 billion in H1 2026, while Puma raised Nerlynx revenue guidance. Olema expects palazestrant results in Q1 2027.